Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
Zacks Investment Research on MSN
Has AbbVie Successfully Navigated Top-line Growth Post Humira LOE?
AbbVie ABBV expects to return to robust revenue growth in 2025, despite the U.S. loss of exclusivity (LOE) for its flagship drug Humira over two years ago. The drug, which went off-patent in January ...
On Friday, AbbVie Inc (NYSE:ABBV) reported an adjusted EPS of $2.46, up 6.5% year over year and beating the consensus of $2.38. The pharmaceutical giant reported sales of $13.34 billion, up 8.4% on a ...
Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients - the latest effort to repurpose ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback